How do you navigate the intricate path of drug development and regulatory compliance to balance innovation with the need for rigorous testing and documentation?
We will explore the stages of drug development needed to perform clinical trials, the intricacies of regulatory frameworks, and the collaborative efforts that drive the advancement of new drug development.
Programme
Learn more about what to consider when you are developing new drugs from bench to bedside from two experienced life science professionals.
Hilde K. Holme
EVP Regulatory & Safety at LINK Medical Research
Hilde has 25 years of experience from the pharmaceutical industry within research, quality control, quality affairs and regulatory affairs, working extensively within all aspects of regulatory CMC.
She has been working in small and large pharmaceutical companies with bringing products from the development phase to commercialization in global markets.
Hilde holds a PhD in Biotechnology from NTNU.
Marit Erlien
Group Manager Regulatory at Link Medical Research
Marit has 20 years’ experience from the regulatory affairs, primary in the human and veterinary pharmaceutical industry (GE Healthcare and PHARMAQ). In addition she has work with regulatory in the food business at IFF.
Her primary expertise is in field of regulatory strategies and CMC (small molecule and vaccines).
Marit holds a MSc in Biochemisty from NTNU.
Digital attendance
If you are unable to attend at 亚博娱乐官网_亚博pt手机客户端登录sparken, but will be able to attend digitally, please send an email to Torunn to get a separate registration link for zoom-participation. Please note that we encourage physical participation for the best experience of the meeting.